CANOPY GROWTH STRENGTHENS COMMITMENT TO CANNABIS-BASED MEDICINES THROUGH COMPLETION OF CANOPY HEALTH INNOVATIONS ACQUISITION
Akumin Inc. (TSX: AKU.U) t to acquire a freestanding, fixed-site outpatient diagnostic imaging business located in Florida for US $27.5 million.
Akumin Inc. (TSX: AKU.U) completed bought deal offering of 8,750,000 common shares at US $4.00 for gross proceeds of US $35,000,000. Clarus Securities Inc. led the offering.
Akumin (TSX: AKU.U) engaged Clarus Securities Inc. for a bought deal of 8,750,000 Common Shares at US $4.00 for gross proceeds of US $35,000,000
DiaMedica Therapeutics (TSX-V: DMA; OTCQB: DMCAF) closed second and final tranche of offering for gross proceeds of approximately US$2.5M. The company raised US $6.3M in two tranches.
Xenon Pharmaceuticals (NASDAQ: XENE) terminated collaborative development and license agreement with Teva Pharmaceuticals and closed share exchange transaction with Biotechnology Value Fund (BVF)
Profound Medical Corp. (TSX-V: PRN; OTCQX: PRFMF) closed previously announced bought for gross proceeds of $34.5M. Canaccord Genuity Corp. led the offering
Cognetivity Neurosciences Ltd. (CSE: CGN) commenced trading on the Canadian Securities Exchange (CSE) under the ticker symbol “CGN”.
HLS Therapeutics Inc. and Automodular Corporation completed RTO transaction